Compare Illumina, Inc. (ILMN) vs Rambus Inc. Common Stock (RMBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Rambus Inc. Common Stock — how do they compare? Illumina, Inc. trades at $271.77 (market cap $40.95B), while Rambus Inc. Common Stock trades at $89 (market cap $10.66B). The key difference: Illumina, Inc. is far larger — about 3.8× Rambus Inc. Common Stock's market cap, and Illumina, Inc. is trading nearer its 52-week high, Rambus Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 84 Days and Rambus Inc. Common Stock for 0 Days on average.
| ILMN | RMBS | |
|---|---|---|
Market Cap | $40.95B | $10.66B |
Volume | 1,893,606 | 2,136,075 |
Sector | Health | Technology |
52-Week High | $293.69 | $170.66 |
52-Week Low | $93.00 | $79.73 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $42.31B | $9.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.76, down 1.77% today but near its 52-week high of $278.99. The stock has surged 94.9% YTD, supported by strong earnings beats and positive technical momentum. Recent quarterly results exceeded expectations with Q2 2026 EPS of $1.31 beating the $1.23 estimate. The company shows improving fundamentals with 2025 net income of $850 million and robust operating cash flow of $1.08 billion.
ILMN presents growth potential through AI integration and S&P 500 inclusion, but faces risks from China headwinds and elevated valuations. Analyst consensus remains bullish with 54% buy ratings, though the $241 consensus price target suggests limited upside. Key catalysts include continued sequencing growth and margin expansion, while competition and cost volatility remain concerns.
Rambus (RMBS) trades at $98.17, down 2.84% over 24 hours, with a neutral technical signal and key support at $96. The company reported strong profitability with a 31.69% net income margin and beat EPS estimates in two of the last three quarters. Recent news highlights its focus on AI infrastructure with new product launches, positioning it to benefit from growing demand for high-speed memory solutions.
The outlook is positive given analyst consensus of a $161.75 price target and 78.57% buy ratings, but risks include high valuation multiples and competitive pressures. Execution on AI-driven growth and maintaining earnings momentum are critical for stock appreciation, while any miss in upcoming results could pressure the premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Rambus Inc. Common Stock
Rambus Inc. is a semiconductor and silicon IP company that licenses chip interface and security technologies, including memory interface chipsets for DDR5 and DDR4 server and client DIMMs, interface IP for PCIe, CXL, and HBM, and security IP such as Root of Trust and memory encryption. It serves data center, AI, automotive, and IoT markets.
Read more on RMBS →
